On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Content
- Protease and inhibitor activities
- Known proteases in the human genome
- Human thiol-dependent cathepsins
- The term "cathepsin"
- Cathepsin K structure, expression and activity
- Cathepsin K structure
- Cathepsin K domain structure
- Cathepsin K tissue distribution
- Cathepsin K substrate specificity
- Inhibition of cathepsin K
- Cleavage of type I collagen by cathepsin K
- What makes cathepsin K a unique collagenase?
- Cathepsin K hydrolyses triple helical collagen
- Activity of cathepsin K
- Effect of chondroitin sulfate (CS)
- Cathepsin K/CS complex identification
- Cathepsin K/chondroitin complex formation
- Collagenolytic activity and complex formation
- Evidence that cathepsin K complexes exist in vivo
- Pycnodysostosis
- Pycno mutant Y212C has no collagenase activity
- Pycno mutant Y212C does not form complexes
- Collagens degradation by MMPs and cathepsins
- Cathepsin K in osteoporosis
- The human skeleton
- Osteoclast activity
- Cathepsin K and its expression in osteoclasts
- Osteoporosis
- Bone resorption assay (pit assay)
- Effect of inhibitors of cathepsins K and L
- Ratio of urine NTx/creatinine
- Cathepsin K and osteoporosis (summary)
- Cathepsin K in arthritis
- Arthritis
- Rheumatoid arthritis (RA)
- Cell types involved in cartilage and bone erosion
- Major bone and cartilage matrix proteins
- Cathepsin K expression in the inflamed synovium
- Expression of cathepsin K in the RA synovium
- Cartilage erosion by CATK+ cells
- Synovial cathepsin K expression and HFCQ
- Scanning EM of MMP/cathepsin-digested cartilage
- Inflammatory reaction involvement of cathepsin K
- MHC class II antigen presentation
- Expression of cathepsins K and S
- Cathepsin K deficiency and CIA
- Collagen-induced arthritis and cathepsins
- Type II CIA (experimental model)
- Ankle thickness of CIA
- Diminished susceptibility to CIA
- Bone erosion and cartilage damage
- Cartilage degradation
- Bone erosion
- Potential cathepsin inhibitor therapy in RA
- Conclusions
Topics Covered
- Cysteine proteases
- Cathepsin family
- Expression of cathepsins and their activity
- Collagen degradation
- Pycnodysostosis
- Cathepsin K in osteoporosis
- Cathepsin K in arthritis
- Mouse model of arthritis
Talk Citation
Bromme, D. (2007, October 1). Cathepsin K in bone and joint diseases [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/XAAT4684.Export Citation (RIS)
Publication History
- Published on October 1, 2007
Financial Disclosures
- Prof. Dieter Bromme has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.